ESMO

ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones

Retrieved on: 
Monday, January 8, 2024
PRC2, CYP, Conference, Lung cancer, ESMO, Partnership, HER2, Breast, Half-life, Prostate cancer, SAN, H3K27me3, CNS, Monocyte, Investment, Webcast, Patient, PIPE, PLK4, TRIM37, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced initial data for its PRC2 inhibitor ORIC-944, operational highlights for 2023, and anticipated upcoming milestones.

Key Points: 
  • Presented initial data from the ongoing Phase 1b dose escalation trial for patients with EGFR or HER2 exon 20 mutated non-small cell lung cancer (NSCLC) at the ESMO Congress 2023.
  • Presented preclinical data for ORIC-114 at ESMO Congress 2023, demonstrating potent activity across atypical mutations in EGFR, thus expanding the potential patient population.
  • Presented preclinical data highlighting a comprehensive biomarker strategy for the ongoing Phase 1b trial in metastatic prostate cancer at the 2023 AACR Annual Meeting.
  • Presented initial data from Phase 1b trial of ORIC-533 in patients with relapsed/refractory multiple myeloma at the 2023 ASH Annual Meeting.

Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation

Retrieved on: 
Friday, January 5, 2024
Conference, ESMO, APC, PRAME, Treatment, Lung cancer, Immune system, IND, TCR, HBV, CMC, HLA, Melanoma, Nivolumab, Research, PIWIL1, Cancer, Standard of care, ImmTAC, Neoplasm, HIV, Ovary, PST, Webcast, Patient, Infection, Endometrium, CTA, Skin, Pharmaceutical industry

The Company is expanding its platform into autoimmune with two first in class new bispecific candidates entering the Company’s pipeline.

Key Points: 
  • The Company is expanding its platform into autoimmune with two first in class new bispecific candidates entering the Company’s pipeline.
  • The Company has updated its corporate presentation to reflect these business and strategic updates.
  • Additionally, the Immunocore management team will discuss these updates during a live and webcast presentation at the 42nd Annual J.P. Morgan Healthcare Conference, on Wednesday January 10, 2024, at 9:00 a.m. Pacific Standard Time (PST).
  • The presentation and webcast will be available in the ‘Investors/Media’ section of Immunocore’s website at www.immunocore.com.

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC

Retrieved on: 
Thursday, January 4, 2024
CBFA2T3, Lung cancer, ESMO, Division, Woman, IND, Ovarian cancer, Drug discovery, PD-1, PROC, Spacecraft, Neutropenia, SAN, Gynecologic Oncology (journal), RAM, Endometrial cancer, Q&A, STRO, University, ASH, Bevacizumab, Patient, Phenotype, Acute myeloid leukemia, Safety, Webcast, ADC, NSCLC, AML, Birth control

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), is hosting an investor webcast today highlighting the significant potential of luveltamab tazevibulin (luvelta), a novel folate receptor-α (FolRα) targeting ADC. The presentation will include an overview of the clinical data supporting luvelta’s broad opportunity to address the unmet need in several FolRα-expressing cancers, including platinum-resistant ovarian cancer (PROC), endometrial cancer, CBFA2T3::GLIS2 (CBF/GLIS; RAM phenotype) acute myeloid leukemia (AML), and non-small cell lung cancer (NSCLC).

Key Points: 
  • “Luvelta has been studied in over 180 patients to-date, and has demonstrated both promising clinical activity and a tolerable safety profile.
  • We are optimistic about its potential to change the cancer treatment landscape,” said Bill Newell, Sutro’s Chief Executive Officer.
  • “This includes the potential to be the first ADC to treat ovarian cancer patients with low to medium FolRα expression, which could double the current eligible patient population relative to the FolRα-targeting ADC on the market.
  • Sutro management and Dr. Monk will participate in a Q&A session at the end of the presentation.

Merck KGaA, Darmstadt, Germany, Expands Colorectal Cancer Portfolio Through Licensing Agreement with Inspirna

Retrieved on: 
Thursday, January 4, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Phase, SLC6A8, Science, Merck Group, CRC, ESMO, Survival, Health care, Colorectal cancer, FOLFIRI, Progression-free survival, Disease, Congress, Randomized controlled trial, Bevacizumab, Merck, Patient, Safety, Head, Pharmaceutical industry

Ompenaclid is currently being evaluated in a Phase II study for the second-line treatment of RAS-mutated (RASmut) advanced or metastatic colorectal cancer (mCRC).

Key Points: 
  • Ompenaclid is currently being evaluated in a Phase II study for the second-line treatment of RAS-mutated (RASmut) advanced or metastatic colorectal cancer (mCRC).
  • The collaboration with Inspirna builds on Merck KGaA, Darmstadt, Germany’s long-standing commitment to the colorectal cancer community.
  • “The data to date validates our belief in ompenaclid as a potential first-in-class therapy for advanced colorectal cancer and underscores the power of our proprietary target discovery platform RNA-DRIVEr™.
  • Furthermore, the parties agreed to collaborate on Inspirna’s SLC6A8 follow-on compounds for which Inspirna will retain US co-development and co-commercialization rights.

Merck Expands Colorectal Cancer Portfolio Through Licensing Agreement with Inspirna

Retrieved on: 
Thursday, January 4, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Phase, SLC6A8, ESMO, CRC, Survival, Health care, Colorectal cancer, FOLFIRI, Progression-free survival, Disease, Congress, Randomized controlled trial, Bevacizumab, Patient, Safety, Head, Pharmaceutical industry

Merck, a leading science and technology company, today announced a licensing agreement with Inspirna, Inc. (New York, NY) for ompenaclid (RGX-202), a first-in-class oral inhibitor of the creatine transport channel SLC6A8, and SLC6A8-targeting follow-on compounds.

Key Points: 
  • Merck, a leading science and technology company, today announced a licensing agreement with Inspirna, Inc. (New York, NY) for ompenaclid (RGX-202), a first-in-class oral inhibitor of the creatine transport channel SLC6A8, and SLC6A8-targeting follow-on compounds.
  • Ompenaclid is currently being evaluated in a Phase II study for the second-line treatment of RAS-mutated (RASmut) advanced or metastatic colorectal cancer (mCRC).
  • The collaboration with Inspirna builds on Merck’s long-standing commitment to the colorectal cancer community.
  • Furthermore, the parties agreed to collaborate on Inspirna’s SLC6A8 follow-on compounds for which Inspirna will retain US co-development and co-commercialization rights.

Inspirna Partners with Merck KGaA, Darmstadt, Germany, to Accelerate Global Development of Ompenaclid (RGX-202)

Retrieved on: 
Thursday, January 4, 2024
Research, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, SLC6A8, Merck Group, CRC, ESMO, Survival, Rasm, Health care, Colorectal cancer, FOLFIRI, Progression-free survival, Congress, Randomized controlled trial, Bevacizumab, Creatine, Merck, RAS, Patient, Safety, Head, Therapy, Pharmaceutical industry

“The data to date validates our belief in ompenaclid as a potential first-in-class therapy for advanced colorectal cancer and underscores the power of our proprietary target discovery platform RNA-DRIVEr™.

Key Points: 
  • “The data to date validates our belief in ompenaclid as a potential first-in-class therapy for advanced colorectal cancer and underscores the power of our proprietary target discovery platform RNA-DRIVEr™.
  • Furthermore, the parties agreed to collaborate on Inspirna’s SLC6A8 follow-on compounds for which Inspirna will retain US co-development and co-commercialization rights.
  • Ompenaclid was well-tolerated, with no dose-limiting toxicities observed in the dose-escalation cohort and combination safety profile comparable to FOLFIRI plus bevacizumab backbone treatment.
  • Inspirna has initiated a Phase 2 double-blind randomized controlled trial in 2L RAS mutant advanced or metastatic mCRC comparing ompenaclid versus placebo plus FOLFIRI and bevacizumab.

Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024

Retrieved on: 
Thursday, January 4, 2024
Oncolytics Biotech, AB, PR, FDA, Breast, Roche, Progression-free survival, Health, AIO, Congress, Society, Pancreatic cancer, Cancer, Oncology, Partnering, Paclitaxel, Anal cancer, Conference, ASCO, ONC, Data, Annual general meeting, Patient, RNA, MBC, TIL, ESMO, Tumor microenvironment, Anal canal, Pancreatic Cancer Action Network, Physician, International, FOLFIRINOX, Survival, Christmas and holiday season, Neoplasm, Toxicity, Poster, Fast Track, Gemcitabine, SCCA, SAN, PDAC, Science Translational Medicine, TSX, Pancreas, Pharmaceutical industry

Overview: "2023 was an outstanding year for Oncolytics and the development of pelareorep as a potential cancer therapy.

Key Points: 
  • Overview: "2023 was an outstanding year for Oncolytics and the development of pelareorep as a potential cancer therapy.
  • "We believe our cash balance and strong data, supported by our active business development program, position us well for 2024."
  • Together, these data provide a strong foundation to support advancing pelareorep into registrational-track studies, starting in 2024," continued Dr Coffey.
  • 2024 Outlook: Dr. Coffey concluded by saying, "Looking ahead to 2024, we expect to initiate the first Phase 3 study for pelareorep in pancreatic cancer.

Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024

Retrieved on: 
Thursday, January 4, 2024
Oncolytics Biotech, AB, PR, FDA, Breast, Roche, Progression-free survival, Health, AIO, Congress, Society, Pancreatic cancer, Cancer, Oncology, Partnering, Paclitaxel, Anal cancer, Conference, ASCO, ONC, Data, Annual general meeting, Patient, RNA, MBC, TIL, ESMO, Tumor microenvironment, Anal canal, Pancreatic Cancer Action Network, Physician, International, FOLFIRINOX, Survival, Christmas and holiday season, Neoplasm, Toxicity, Poster, Fast Track, Gemcitabine, SCCA, SAN, PDAC, Science Translational Medicine, TSX, Pancreas, Pharmaceutical industry

Overview: "2023 was an outstanding year for Oncolytics and the development of pelareorep as a potential cancer therapy.

Key Points: 
  • Overview: "2023 was an outstanding year for Oncolytics and the development of pelareorep as a potential cancer therapy.
  • "We believe our cash balance and strong data, supported by our active business development program, position us well for 2024."
  • Together, these data provide a strong foundation to support advancing pelareorep into registrational-track studies, starting in 2024," continued Dr Coffey.
  • 2024 Outlook: Dr. Coffey concluded by saying, "Looking ahead to 2024, we expect to initiate the first Phase 3 study for pelareorep in pancreatic cancer.

Sermonix Pharmaceuticals Announces Publication of ELAINE-1 and ELAINE-2 Trial Results in Annals of Oncology

Retrieved on: 
Monday, December 11, 2023
Editorial, Quality of life, ESR1, Hospital, ESMO, Medicine, ASCO, Woman, Breast cancer, Fulvestrant, Annals of Oncology, Eli Lilly, Breast, Business model, Progression-free survival, Massachusetts General Hospital, Congress, Society, Trial of the century, International Society, Mutation, Annual general meeting, Neoplasm, Oncology, Patient, PFS, Therapy, Pharmaceutical industry

Also, 30.7% of patients on lasofoxifene achieved a PFS of 12 months compared to 14.1% on fulvestrant.

Key Points: 
  • Also, 30.7% of patients on lasofoxifene achieved a PFS of 12 months compared to 14.1% on fulvestrant.
  • Results were initially shared at a poster discussion session during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and updated in June at ASCO 2023.
  • Annals of Oncology provides rapid and efficient peer-review publications on innovative cancer treatments or translational work related to oncology and precision medicine.
  • To learn more about Sermonix Pharmaceuticals and lasofoxifene, visit SermonixPharma.com .

Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma

Retrieved on: 
Monday, December 11, 2023
IO, ESMO, Prognosis, Antibody, FDA, FTD, Melanoma, SAN, Congress, Novartis, Neoplasm, MEK, Oncology, NRAS, Patient, Safety, Journal, Binimetinib, Pharmaceutical industry

SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to naporafenib in combination with trametinib (MEKINIST®) for the treatment of adult patients with unresectable or metastatic melanoma who have progressed on, or are intolerant to, an anti‑programmed death-1 (ligand 1) (PD‑(L)1)-based regimen, and whose tumors contain an NRAS mutation (NRASm). Naporafenib is an orally available, Phase 3-ready pan-RAF inhibitor with a potential first-in-class and best-in-class profile in NRASm melanoma and other RAS/MAPK pathway-altered solid tumors.

Key Points: 
  • Naporafenib is an orally available, Phase 3-ready pan-RAF inhibitor with a potential first-in-class and best-in-class profile in NRASm melanoma and other RAS/MAPK pathway-altered solid tumors.
  • “The outcomes for patients with NRASm melanoma after frontline immunotherapy (IO) treatment are dismal with low response rates and short median progression free survival (mPFS).
  • Effective treatment options are needed for patients following progression on frontline IO with anti-CTLA-4 and/or anti-PD-(L)1 antibodies.
  • Erasca recently reported that End of Phase 2 meetings with the FDA and European health authorities confirmed the SEACRAFT-2 Phase 3 trial design and provided clarity on the registrational pathway.